Author
Listed:
- Federico Gaiti
(New York Genome Center
Weill Cornell Medicine)
- Ronan Chaligne
(New York Genome Center
Weill Cornell Medicine)
- Hongcang Gu
(Broad Institute of MIT and Harvard)
- Ryan M. Brand
(New York Genome Center
Weill Cornell Medicine)
- Steven Kothen-Hill
(New York Genome Center
Weill Cornell Medicine)
- Rafael C. Schulman
(New York Genome Center
Weill Cornell Medicine)
- Kirill Grigorev
(Weill Cornell Medicine)
- Davide Risso
(Weill Cornell Medicine
University of Padova)
- Kyu-Tae Kim
(New York Genome Center
Weill Cornell Medicine)
- Alessandro Pastore
(Memorial Sloan Kettering Cancer Center)
- Kevin Y. Huang
(New York Genome Center
Weill Cornell Medicine)
- Alicia Alonso
(Weill Cornell Medicine)
- Caroline Sheridan
(Weill Cornell Medicine)
- Nathaniel D. Omans
(New York Genome Center
Weill Cornell Medicine)
- Evan Biederstedt
(New York Genome Center
Weill Cornell Medicine)
- Kendell Clement
(Broad Institute of MIT and Harvard)
- Lili Wang
(City of Hope)
- Joshua A. Felsenfeld
(Weill Cornell Medicine)
- Erica B. Bhavsar
(Weill Cornell Medicine)
- Martin J. Aryee
(Broad Institute of MIT and Harvard
Harvard T.H. Chan School of Public Health)
- John N. Allan
(Weill Cornell Medicine)
- Richard Furman
(Weill Cornell Medicine)
- Andreas Gnirke
(Broad Institute of MIT and Harvard)
- Catherine J. Wu
(Broad Institute of MIT and Harvard
Dana-Farber Cancer Institute)
- Alexander Meissner
(Broad Institute of MIT and Harvard
Max Planck Institute for Molecular Genetics)
- Dan A. Landau
(New York Genome Center
Weill Cornell Medicine)
Abstract
Genetic and epigenetic intra-tumoral heterogeneity cooperate to shape the evolutionary course of cancer1. Chronic lymphocytic leukaemia (CLL) is a highly informative model for cancer evolution as it undergoes substantial genetic diversification and evolution after therapy2,3. The CLL epigenome is also an important disease-defining feature4,5, and growing populations of cells in CLL diversify by stochastic changes in DNA methylation known as epimutations6. However, previous studies using bulk sequencing methods to analyse the patterns of DNA methylation were unable to determine whether epimutations affect CLL populations homogeneously. Here, to measure the epimutation rate at single-cell resolution, we applied multiplexed single-cell reduced-representation bisulfite sequencing to B cells from healthy donors and patients with CLL. We observed that the common clonal origin of CLL results in a consistently increased epimutation rate, with low variability in the cell-to-cell epimutation rate. By contrast, variable epimutation rates across healthy B cells reflect diverse evolutionary ages across the trajectory of B cell differentiation, consistent with epimutations serving as a molecular clock. Heritable epimutation information allowed us to reconstruct lineages at high-resolution with single-cell data, and to apply this directly to patient samples. The CLL lineage tree shape revealed earlier branching and longer branch lengths than in normal B cells, reflecting rapid drift after the initial malignant transformation and a greater proliferative history. Integration of single-cell bisulfite sequencing analysis with single-cell transcriptomes and genotyping confirmed that genetic subclones mapped to distinct clades, as inferred solely on the basis of epimutation information. Finally, to examine potential lineage biases during therapy, we profiled serial samples during ibrutinib-associated lymphocytosis, and identified clades of cells that were preferentially expelled from the lymph node after treatment, marked by distinct transcriptional profiles. The single-cell integration of genetic, epigenetic and transcriptional information thus charts the lineage history of CLL and its evolution with therapy.
Suggested Citation
Federico Gaiti & Ronan Chaligne & Hongcang Gu & Ryan M. Brand & Steven Kothen-Hill & Rafael C. Schulman & Kirill Grigorev & Davide Risso & Kyu-Tae Kim & Alessandro Pastore & Kevin Y. Huang & Alicia Al, 2019.
"Epigenetic evolution and lineage histories of chronic lymphocytic leukaemia,"
Nature, Nature, vol. 569(7757), pages 576-580, May.
Handle:
RePEc:nat:nature:v:569:y:2019:i:7757:d:10.1038_s41586-019-1198-z
DOI: 10.1038/s41586-019-1198-z
Download full text from publisher
As the access to this document is restricted, you may want to search for a different version of it.
Corrections
All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:nat:nature:v:569:y:2019:i:7757:d:10.1038_s41586-019-1198-z. See general information about how to correct material in RePEc.
If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.
We have no bibliographic references for this item. You can help adding them by using this form .
If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.
For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.nature.com .
Please note that corrections may take a couple of weeks to filter through
the various RePEc services.